These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

224 related articles for article (PubMed ID: 19205138)

  • 1. Drug expenditure in Ireland 1997-2007.
    Barry M; Molloy D; Usher C; Tilson L
    Ir Med J; 2008; 101(10):299-302. PubMed ID: 19205138
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Public drug expenditure in the Republic of Ireland.
    Barry M; Usher C; Tilson L
    Expert Rev Pharmacoecon Outcomes Res; 2010 Jun; 10(3):239-45. PubMed ID: 20545588
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cost containment interventions introduced on the community drugs schemes in Ireland-evaluation of expenditure trends using a national prescription claims database.
    Usher C; Tilson L; Bennett K; Barry M
    Clin Ther; 2012 Mar; 34(3):632-9. PubMed ID: 22381716
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pricing and reimbursement of pharmaceuticals in Italy.
    Folino-Gallo P; Montilla S; Bruzzone M; Martini N
    Eur J Health Econ; 2008 Aug; 9(3):305-10. PubMed ID: 18566845
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pharmacoeconomics of lipid lowering therapy in Ireland.
    Barry M; Heerey A; Sheehan O; Ryan M; McCulloch D; Feely J
    Ir Med J; 1999; 92(7):430-2. PubMed ID: 10967865
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Risk-sharing schemes: a new paradigm in adopting innovative pharmaceuticals].
    Hammerman A; Greenberg D
    Harefuah; 2012 Jun; 151(6):364-7, 376. PubMed ID: 22991869
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Recent developments in pricing and reimbursement of medicines in Ireland.
    Barry M; Tilson L
    Expert Rev Pharmacoecon Outcomes Res; 2007 Dec; 7(6):605-11. PubMed ID: 20528322
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pharmaceutical pricing and reimbursement reforms in Greece.
    Yfantopoulos J
    Eur J Health Econ; 2008 Feb; 9(1):87-97. PubMed ID: 17619920
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The effect of newer drugs on health spending: do they really increase the costs?
    Civan A; Köksal B
    Health Econ; 2010 May; 19(5):581-95. PubMed ID: 19404925
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pharmaceuticals and medical devices: Medicare Part D. End-of-year issue brief.
    Chaps NA
    Issue Brief Health Policy Track Serv; 2009 Jan; ():1-26. PubMed ID: 19301435
    [No Abstract]   [Full Text] [Related]  

  • 11. Pharmacoeconomic evaluation in Ireland: a review of the process.
    Tilson L; O'Leary A; Usher C; Barry M
    Pharmacoeconomics; 2010; 28(4):307-22. PubMed ID: 20222754
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Government regulation of pricing and reimbursement of prescription medicines: results of a recent multi-country review.
    Kingham R; Wheeler J
    Food Drug Law J; 2009; 64(1):101-14. PubMed ID: 19998574
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The concentration and persistence of health care expenditures and prescription drug expenditures in Medicare beneficiaries with Alzheimer disease and related dementias.
    Lin PJ; Biddle AK; Ganguly R; Kaufer DI; Maciejewski ML
    Med Care; 2009 Nov; 47(11):1174-9. PubMed ID: 19786913
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Prescription drugs and the changing concentration of health care expenditures.
    Zuvekas SH; Cohen JW
    Health Aff (Millwood); 2007; 26(1):249-57. PubMed ID: 17211035
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Recent developments in pharmacoeconomic evaluation in Ireland.
    Tilson L; Barry M
    Expert Rev Pharmacoecon Outcomes Res; 2010 Jun; 10(3):221-4. PubMed ID: 20545585
    [No Abstract]   [Full Text] [Related]  

  • 16. The impact of co-payment increases on dispensings of government-subsidised medicines in Australia.
    Hynd A; Roughead EE; Preen DB; Glover J; Bulsara M; Semmens J
    Pharmacoepidemiol Drug Saf; 2008 Nov; 17(11):1091-9. PubMed ID: 18942671
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cluster analysis of state Medicaid prescription drug benefit programs based on potential determinants of per capita drug expenditure.
    Roy S; Madhavan SS
    Res Social Adm Pharm; 2009 Mar; 5(1):51-62. PubMed ID: 19285289
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Analysis of a pharmaceutical risk sharing agreement based on the purchaser's total budget.
    Zaric GS; O'brien BJ
    Health Econ; 2005 Aug; 14(8):793-803. PubMed ID: 15685669
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Chronic catastrophes: exploring the concentration and sustained nature of ambulatory prescription drug expenditures in the population of British Columbia, Canada.
    Hanley GE; Morgan S
    Soc Sci Med; 2009 Mar; 68(5):919-24. PubMed ID: 19135288
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Value-Based Pricing and Patient Access for Specialty Drugs.
    Robinson JC; Howell S; Pearson SD
    JAMA; 2018 Jun; 319(21):2169-2170. PubMed ID: 29801023
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 12.